About 13 results found for searched term "Cholecystokinin Receptor" (0.127 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5923 | Rebamipide | COX |
| OPC-12759 | ||
| Rebamipide (OPC12759) is a cholecystokinin-1 (CCK1) receptor inhibitor that inhibits [125I]BH-CCK-8S with an IC50 of 37.7 μM. Rebamipide is an orally effective gastroprotective agent. Rebamipide enhances the production of endogenous PGs (particularly intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide also has anti-proliferative activity against gastric cancer cells. | ||
| M7327 | Lintitript | Cholecystokinin Receptor |
| SR 27897 | ||
| Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). | ||
| M8234 | Loxiglumide | Others |
| CR-1505 | ||
| Loxiglumide is a small-molecule antagonist of the cholecystokinin receptor CCKA. | ||
| M9311 | Lorglumide sodium salt | Cholecystokinin Receptor |
| CR-1409 sodium salt | ||
| Lorglumide (CR-1409) sodium salt is a potent cholecystokinin (CCK) receptor antagonist. | ||
| M9316 | Ceruletide | Animal Modeling |
| Caerulein; Cerulein; FI-6934 | ||
| Ceruletide is a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, acts as a cholecystokinin receptor agonist. | ||
| M9320 | Gastrin-I (human) | Cholecystokinin Receptor |
| Gastrin-1 | ||
| Gastrin-I (human) is the endogenous peptide produced in the stomach, which increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor. | ||
| M10420 | Proglumide | Others |
| Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. | ||
| M13474 | Pristinamycin IA | Antibiotic |
| Mikamycin B; Mikamycin IA | ||
| Pristinamycin IA (Mikamycin B; Mikamycin IA), a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, is a potent cholecystokinetic agent, and acts as a cholecystokinin receptor agonist. | ||
| M29195 | Nastorazepide | Cholecystokinin Receptor |
| Z-360 | ||
| Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Target：CCK-2 in vitro: Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. Check for active clinical trials or closed clinical trials using this agent. in vivo: Z-360 is a novel orally active CCK-2/gastrin receptor antagonist, significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Z-360 combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice. | ||
| M31110 | V-9-M cholecystokinin nonapeptide | Glucagon Receptor |
| V-9-M cholecystokinin nonapeptide is a glucagon-like peptide-1 (GLP-1) receptor agonist. | ||
| M31358 | [Leu15]-Gastrin I (human) | Cholecystokinin Receptor |
| [Leu15]-Gastrin I (human) is a peptide that acts via cholecystokinin (CCK) or CCK-B receptor (CCK-BR). | ||
| M53222 | N-acetyl CCK-(26-30) amide | Cholecystokinin Receptor |
| N-acetyl CCK-(26-30) amide (CCK-(26-30) (sulfated)) is a cholecystokinin (CCK) receptor antagonist. | ||
| M56166 | CI-988 | Cholecystokinin Receptor |
| CI-988 (PD134308) is a potent, selective and orally active CCK2R (cholecystokinin 2 receptor) antagonist with an IC50 of 1.7 nM for mouse cortex CCK2. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
